Astellas’ COVID-19 Pandemic Response
- Now more than ever, we are working to ensure that patients have access to and can afford their critical Astellas medications. In the U.S., Astellas has implemented changes to its patient assistance programs as part of the company's ongoing commitment to ensuring that patients have access to our products. Astellas Pharma Support SolutionsSM offers support to patients needing access and reimbursement assistance. Click here to read more.
- We have assessed our supply chain to ensure that the supply, manufacturing and distribution of Astellas products in the U.S. will not be impacted. Our patients will continue to be able to receive all approved Astellas medicines, including our oncology and transplantation therapies, without interruption related to COVID-19. We are constantly evaluating our supply chain to avoid any supply chain shortage. Click here for the latest updates on supply status.
- To help ensure patient safety and alleviate strain on healthcare resources, we are implementing changes to our clinical trial operations. In countries with rapid growth of new COVID-19 cases (including the U.S.), we are suspending start-up activities involving study sites for new interventional clinical studies to prevent the risk of infection. Click here for more information on clinical trial operations.